Byrn, Inc. (BRRN)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-11

Key Insights

  • MEDO Healthcare LLC acquired 84.7% voting control of Bryn Inc. by purchasing 10 million Series A-1 Preferred Shares for only $175,000, representing an extreme valuation discount and indicating severe financial distress or a restructuring transaction.
  • Complete management change occurred with founder David Lazar resigning as sole director and officer, replaced by John Leo (CEO) and Arthur Magee (CFO/Secretary), suggesting strategic repositioning under new leadership with significant financial services and investment banking experience.
  • The transaction reflects a change of control event where voting power shifted dramatically from Lazar (previously sole control) to MEDO Healthcare (84.7% voting power), with actual operational control held by Miriam Mizrachi as Manager of Ashford Capital LLC.
  • John Leo's appointment as CEO brings extensive experience in investment banking, M&A, and capital markets across 100+ U.S. and 50+ foreign companies, along with recent executive experience at a financial institution, suggesting potential strategic repositioning or acquisition activity ahead.
Annual Report Filed: 2026-04-02

Key Insights

  • Byrn, Inc. (BRRN) appears to be a shell company with no active business operations as of December 31, 2025.
  • The company has not filed any reports required under Section 13 or 15(d) of the Exchange Act in the past 12 months.
  • Byrn, Inc. has not submitted any Interactive Data Files as required by Regulation S-T in the past 12 months.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.